Chu, Quincy Siu-chung
Bouganim, Nathaniel
Fortier, Caroline
Zaknoen, Sara
Stille, John R.
Kremer, Jill D.
Yuen, Eunice
Hui, Yu-Hua
de la Peña, Amparo
Lithio, Andrew
Smith, Patricia S.
Batist, Gerald
Article History
Received: 3 November 2020
Accepted: 9 December 2020
First Online: 22 January 2021
Compliance with ethical standards
:
: This trial was conducted in accordance with the Good Clinical Practice guidelines of the International Conference on Harmonisation and with the principles of the Declaration of Helsinki. All trial protocols and documentation were approved by the institutional review board or independent ethics committee at each investigational site: McGill University Health Centre Research Ethics Board (Project number: MP-37-2017-2682); Health Research Ethics Board of Alberta-Cancer Committee (Ethics ID: HREBA.CC-17-0102_REN3). Written informed consent was obtained from all patients before participation in any study-related activities.
: Not applicable.
: QC, NB, and GB declare no potential conflict of interest related to this submitted work. CF was the CEO of AurKa Pharma Inc. while the clinical research described in this article was conducted. SZ has acted as a consultant for Daiichi Sankyo and Mirati. JRS, JDK, EY, YHH, AdlP, AL, and PSS are employees of Eli Lilly and Company.
: Not applicable.